Apogee Therapeutics, Inc. (APGE) announced positive 16-week data from Part A of the Phase 2 APEX clinical trial of APG777, a potential anti-IL-13 antibody, in patients with moderate-to-severe atopic dermatitis. The trial met all primary and key secondary endpoints and exceeded trial objectives, including 71.0% decrease from baseline in EASI at Week 16. Data readout from the maintenance phase of APEX Part A, testing 3- and 6-month maintenance dosing, is expected in the first half of 2026.
"Today's results from APEX Part A demonstrate strong efficacy results across all key endpoints," said Carl Dambkowski, Chief Medical Officer of Apogee.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.